Denmark-based Chr. Hansen has signed an exclusive agreement with biotech company Probiomics Ltd., securing the rights to market the patented probiotic strain Lactobacillus fermentum PCC, which has documented benefits to immune health. Several clinical studies in various indication areas have been conducted involving PCC, which has shown to be effective in relation to atopic dermatitis, as an adjuvant to flu vaccine, and in supporting immune response in athletes.